Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.
about
New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.Lung Microbiota Changes Associated with Chronic Pseudomonas aeruginosa Lung Infection and the Impact of Intravenous Colistimethate Sodium.Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis.Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.Strategies for the safe use of colistin.An Update on Aerosolized Antibiotics for Treating Hospital-Acquired and Ventilator-Associated Pneumonia in Adults.Nebulized antibiotics in mechanically ventilated patients: a challenge for translational research from technology to clinical care.Urinary Concentrations of Colistimethate and Formed Colistin after Intravenous Administration in Patients with Multidrug-Resistant Gram-Negative Bacterial Infections.Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.Colistin: still a lifesaver for the 21st century?Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.Clinical Pharmacokinetics and Pharmacodynamics of Colistin.Pulmonary Pharmacokinetics of Colistin Following Administration of Dry Powder Aerosols in Rats.Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects.Efficacy of nebulized colistin-based therapy without concurrent intravenous colistin for ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii.Potential Toxicity of Polymyxins in Human Lung Epithelial Cells.Nebulized antibiotics in mechanically ventilated patients: roadmap and challenges.New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.Treatment of Ventilator-Associated Pneumonia Using Intravenous Colistin Alone or in Combination with Inhaled Colistin in Critically Ill Children.Aerosol delivery during invasive mechanical ventilation: a systematic review.Mechanism-based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model.Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model.Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models.Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.Pharmacokinetics of Colistin Methansulphonate (CMS) and Colistin after CMS Nebulisation in Baboon Monkeys.
P2860
Q30856181-6434EF78-25FF-4976-8358-E13D4AE707B0Q36257805-E3961324-550C-48A3-B85C-209683DEAEA8Q36644676-FBA28EB7-B0F7-405D-8296-8AC7AF5076CFQ37538748-F9DB182E-9C5B-4FAA-8AEC-89BD04272F92Q38548658-B66F6B07-69A8-4CB6-A10E-DEE7AB3C1991Q38640441-9110B025-327D-451C-99A6-9DCAB6083D3FQ38647453-25052330-8032-4695-BD30-11C0653D72E1Q38677017-11D58DCD-BB7F-4DB0-95F0-272AD9E85512Q38755683-17C32118-6D5A-4004-9174-04872461D2DCQ38940249-5BA7758D-38AD-4CDF-BC3D-0874FB83D6E6Q38994000-B66D8579-1CDF-4264-82FF-57759C541ED0Q39057108-A7A6CE8F-33D6-47EC-B813-C35B1B93C355Q39333751-BA51515B-B597-43B1-96EA-5BD7F8BC38B0Q40093588-4198156D-BF97-4765-923A-2519A8D2303CQ40121090-17B49F4E-0453-481B-8217-D7FBDD75871DQ40234980-41FCB7DC-44D8-40AE-BFD9-5D81CEECF0C0Q40248118-70850749-836F-4D3F-A100-108E7D07EB72Q40422166-D58B7D76-3D65-4C41-B1E1-A6F206CB6EBAQ41027375-0C674B41-8266-481C-A38A-B37AFA02420CQ41260939-2132C86B-CCE8-47B4-B56E-6A5204404540Q42654272-A28C41C8-DC71-47C8-8E83-00089CAD056EQ47273930-E22F96A9-31CB-4C4A-8E87-89ACC7CCAA57Q47327699-8AC58BEC-AA75-4987-A028-000E757D40E7Q47391725-C3BD130B-D7C1-4880-B7C3-D58EDE652D07Q47661746-DB2E6B93-CC2C-4653-80F1-BD042BDBEEFCQ53217740-C66BBE85-E6FC-48FC-840B-307EB6924E27
P2860
Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Comparison of intrapulmonary a ...... MS in critically ill patients.
@ast
Comparison of intrapulmonary a ...... MS in critically ill patients.
@en
Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate
@nl
type
label
Comparison of intrapulmonary a ...... MS in critically ill patients.
@ast
Comparison of intrapulmonary a ...... MS in critically ill patients.
@en
Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate
@nl
prefLabel
Comparison of intrapulmonary a ...... MS in critically ill patients.
@ast
Comparison of intrapulmonary a ...... MS in critically ill patients.
@en
Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate
@nl
P2860
P50
P356
P1476
Comparison of intrapulmonary a ...... CMS in critically ill patients
@en
P2093
Matthieu Jacobs
Patrice Gobin
P2860
P304
P356
10.1128/AAC.03510-14
P407
P577
2014-09-29T00:00:00Z